Translational Model to Predict Pulmonary Pharmacokinetics and Efficacy in Man for Inhaled Bronchodilators

• In: Poster Presentation
• At: Stockholm (Sweden) (2017)
• Type: Poster
• Poster code: P-A-077-Monday
• By: HENDRICKX, Adriaan (AstraZeneca, DMPK, Mölndal, Sweden)
• Co-author(s): Adriaan Hendrickx: RIA DMPK, AstraZeneca, Mölndal, Sweden
  Eva Lamm Bergström: RIA DMPK, AstraZeneca, Mölndal, Sweden
  David L. I. Janzén: CVMD DMPK, AstraZeneca, Mölndal, Sweden
  Markus Fridén: RIA DMPK, AstraZeneca, Mölndal, Sweden
  Ulf Eriksson: RIA QCP, AstraZeneca, Mölndal, Sweden
  Ken Grime: RIA DMPK, AstraZeneca, Mölndal, Sweden
  Douglas Ferguson: Oncology DMPK, AstraZeneca, Mölndal, Sweden
  
• Abstract:

  Backgrounds

  Inhaled drug therapy is typically used for targeting the lung whilst minimizing systemic exposure in order to improve the benefit/risk margin for treatments of respiratory disease.

  Aims

  The aim of current study was to develop a translational modelling framework for capturing both lung and systemic PK and efficacy after pulmonary delivery
  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login